0 Replies
Servier selects third cardiovascular target triggering the first milestone under the collaboration
SURESNES, France, and BOULDER, Colo., May 23, 2013 – Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise in the development of treatments for cardiovascular diseases, and miRagen Therapeutics,... Contine Reading & Discuss→
0 Replies
Phase 1 Clinical Trial of Anticancer Drug MRX34 Underway
AUSTIN, TX (May 13, 2013)– Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer,
announced today that it has initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial... Contine Reading & Discuss→
0 Replies
HOERSHOLM, Denmark and BOULDER, Colo., Jan. 8, 2013 /PRNewswire/ — Santaris Pharma A/S and miRagen Therapeutics, Inc. today announced that they have expanded their existing partnership in the field of microRNA therapeutics.
Under the expanded agreement, miRagen obtains a broad non-exclusive license in the miRNA therapeutics field for therapeutics research and... Contine Reading & Discuss→
0 Replies
Institutional Investment Is One of the Largest Ever for a Texas Biotechnology Company
Austin, TX – October 24, 2012
Mirna Therapeutics Inc. (Mirna), a biopharmaceutical company focused on the development and commercialization of microRNA (miRNA) therapeutics in cancer, announced today the completion of a $34.5 million Series C financing.
The... Contine Reading & Discuss→
0 Replies
Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
LA JOLLA, Calif., Aug. 15, 2012 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a... Contine Reading & Discuss→
0 Replies
Focused on three exclusive microRNA targets
LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for... Contine Reading & Discuss→
0 Replies
CINCINNATI, March 28, 2012 /PRNewswire-USNewswire/ — Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).
Scientists from Cincinnati Children’s Hospital Medical Center say the finding opens the potential for new molecular targets to... Contine Reading & Discuss→
0 Replies
-New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney
-Regulus, in partnership with Sanofi, developing novel anti-fibrotic therapies targeting microRNAs
B.N. Chau et al.
“MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways”
Sci Transl Med 15 February 2012:
Vol. 4, Issue 121,... Contine Reading & Discuss→
